What is Roth Capital’s Estimate for CLRB Q1 Earnings?

Cellectar Biosciences, Inc. (NASDAQ:CLRB) – Analysts at Roth Capital increased their Q1 2025 earnings per share estimates for shares of Cellectar Biosciences in a note issued to investors on Wednesday, December 11th. Roth Capital analyst J. Aschoff now forecasts that the biopharmaceutical company will post earnings of ($0.18) per share for the quarter, up from their prior forecast of ($0.26). The consensus estimate for Cellectar Biosciences’ current full-year earnings is ($1.59) per share. Roth Capital also issued estimates for Cellectar Biosciences’ Q2 2025 earnings at ($0.16) EPS, Q3 2025 earnings at ($0.16) EPS, Q4 2025 earnings at ($0.16) EPS, FY2025 earnings at ($0.66) EPS, FY2026 earnings at ($0.62) EPS, FY2027 earnings at ($0.59) EPS and FY2028 earnings at ($0.18) EPS.

Cellectar Biosciences (NASDAQ:CLRB) last posted its earnings results on Tuesday, October 29th. The biopharmaceutical company reported ($0.51) earnings per share for the quarter.

Several other equities research analysts have also issued reports on the company. StockNews.com raised Cellectar Biosciences to a “sell” rating in a research note on Thursday, September 26th. LADENBURG THALM/SH SH began coverage on Cellectar Biosciences in a report on Thursday, December 5th. They issued a “buy” rating and a $13.00 price target on the stock. Finally, Oppenheimer reissued a “market perform” rating on shares of Cellectar Biosciences in a report on Wednesday, December 11th.

Cellectar Biosciences Price Performance

CLRB opened at $0.26 on Monday. The firm has a market capitalization of $10.83 million, a P/E ratio of -0.15 and a beta of 0.89. Cellectar Biosciences has a one year low of $0.23 and a one year high of $4.45. The company has a fifty day moving average price of $1.70 and a 200-day moving average price of $2.13.

Institutional Investors Weigh In On Cellectar Biosciences

A number of large investors have recently added to or reduced their stakes in CLRB. Oppenheimer & Co. Inc. purchased a new position in shares of Cellectar Biosciences during the third quarter worth approximately $27,000. Sequoia Financial Advisors LLC bought a new position in shares of Cellectar Biosciences during the 3rd quarter valued at $51,000. XTX Topco Ltd grew its holdings in shares of Cellectar Biosciences by 432.4% during the 2nd quarter. XTX Topco Ltd now owns 63,304 shares of the biopharmaceutical company’s stock valued at $158,000 after purchasing an additional 51,413 shares during the last quarter. Geode Capital Management LLC raised its position in Cellectar Biosciences by 3.3% in the 3rd quarter. Geode Capital Management LLC now owns 352,452 shares of the biopharmaceutical company’s stock worth $754,000 after purchasing an additional 11,266 shares during the period. Finally, Vanguard Group Inc. lifted its stake in Cellectar Biosciences by 146.7% in the first quarter. Vanguard Group Inc. now owns 1,191,081 shares of the biopharmaceutical company’s stock worth $4,741,000 after purchasing an additional 708,191 shares during the last quarter. Hedge funds and other institutional investors own 16.41% of the company’s stock.

About Cellectar Biosciences

Cellectar Biosciences, Inc, a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer.